Applicability of KEAP1 E3 Ligase to the PROTAC Platform

초록

Proteolysis-targeting chimeras (PROTACs) represent an innovative approach for drug design involving the creation of a heterobifunctional molecule. This molecule uses an E3 ligase to target and degrade specific proteins via the ubiquitin-proteasome system (UPS). The three essential components of PROTAC are a ligand for the protein of interest (POI), a binder to recruit an E3 ligase, and a linker connecting these two elements. Given the relatively large number of E3 ligases in the human body (>600), only a few such as VHL, CRBN, MDM2, cIAP1, DCAF15, RNF4, and RNF114 have been used in existing PROTACs. PROTACs facilitate degradation of pathological proteins through the UPS pathway. Consequently, the identification of a broad range of E3 ligase recruiters is crucial for advancing targeted proteindegradation (TPD) strategies. In this study, we focused on designing KEAP1 binder PROTACs, using a selective, potent small-molecule inhibitor of KEAP1 as an E3 ligase recruiter. It was linked to JQ1 (a POI ligand) via a flexible aliphatic linker. Our compound SD-2406, with KEAP1 E3 ligase recruiter, effectively degraded BRD4 target proteins in LNCaP cells. This demonstrates the potential of expanding the E3 ligase toolbox for the development of PROTAC technology.

키워드